GLP-1 Medicines in Australia: The Facts, and the Bloods Worth Having

What this page can and cannot tell you

FORM is a pathology testing service — we do not prescribe, dispense, sell, compound or arrange supply of GLP-1 medicines or any other medicine, and Australian advertising law limits what any public website may say about a prescription medicine.

If you searched for GLP-1 medicines in Australia, such as semaglutide (marketed under brand names including Wegovy), you were probably looking for one of three things: whether they are available, what they cost, or whether one would suit you. We cannot answer any of those, and it is worth being straightforward about why rather than burying it.

Semaglutide is a Schedule 4 Prescription Only Medicine under the Poisons Standard. Under the Therapeutic Goods Act 1989 and the Therapeutic Goods Advertising Code, prescription medicines must not be advertised to the public in Australia. That prohibition is broad: it covers claims about effectiveness, availability statements, price promotion, comparisons between products, and anything that would encourage someone to seek out a particular medicine. A site that answers 'is it right for me?' about a Schedule 4 medicine is, in the regulator's terms, advertising it.

So this page does the two honest things available to it. It states the regulatory facts, which are public and non-promotional. And it covers the pathology — which is our actual field, is not restricted, and is the thing most people in this situation genuinely do not have sorted.

The factual position in Australia

Semaglutide is registered on the Australian Register of Therapeutic Goods and scheduled as a Prescription Only Medicine, so it is lawfully supplied only against a prescription written by an authorised prescriber for a person they have assessed.

Practically, that means there is no lawful route to a GLP-1 medicine in Australia that does not run through a registered practitioner making an individual clinical assessment. Products offered without that, including anything shipped from overseas or sold as a 'research' preparation, sit outside the regulated supply chain — the TGA has published warnings about both unapproved imports and compounded GLP-1 preparations, and we point to those rather than commenting further.

Supply of GLP-1 medicines in Australia has also been affected by shortages at various points, driven by global manufacturing constraints. The TGA maintains a public Medicine Shortage Reports Database that records current and resolved shortages by product; that database, not a third-party blog, is the authoritative source on whether something is currently in short supply.

Whether a particular medicine is subsidised is a separate question again, decided by the Pharmaceutical Benefits Advisory Committee and recorded on the PBS website. We cover the current PBS position for GLP-1 medicines on a dedicated page.

• Schedule 4 Prescription Only Medicine under the Poisons Standard (SUSMP).
• Lawfully supplied only on a prescription from a registered Australian practitioner who has assessed you.
• Current shortage status is published in the TGA Medicine Shortage Reports Database.
• TGA-approved Consumer Medicine Information leaflets are the correct place to read about a specific product; your pharmacist can provide one.

Where pathology actually fits

Whatever happens with treatment, the metabolic markers underneath — HbA1c, fasting glucose, lipids, liver function and thyroid — are worth documenting before anything changes and repeating as it does.

There is a pattern we see constantly and it is worth naming. Someone spends weeks researching a medicine, has a consultation, and begins medically supervised treatment — and six months later nobody can say what their liver enzymes, lipids or HbA1c looked like beforehand, because they were never measured. When a mildly abnormal number turns up later, that missing baseline turns a two-minute conversation into a work-up.

It also cuts the other way. A number of the conditions that sit underneath weight gain — fatty liver, insulin resistance, subclinical thyroid disease, dyslipidaemia — are common, silent, and entirely findable on a routine blood panel. Some people who go looking for a weight treatment discover an untreated thyroid problem or an HbA1c already in the diabetic range, both of which change the clinical picture and both of which are their doctor's to act on.

That is the argument for doing bloods first, and it holds regardless of what any medicine costs, whether it is subsidised, or whether treatment ever begins.

Which FORM panel covers these markers

The full baseline metabolic set is carried by the standard FORM Australia panels, and each marker can also be selected individually.

• GLP-1 monitoring blood panel — The marker-by-marker breakdown with Australian ranges and a conventional retest rhythm.
• Australian blood test panels (Essential to Ultra) — Essential covers HbA1c, glucose, lipids, LFTs and thyroid; indicatively from A$299 in pre-sale.
• Build your own Australian panel — Select only the metabolic markers you want, in one blood draw.
• What GLP-1 treatment costs in Australia — The five cost categories, PBS versus private scripts, and where pathology fits.

How testing with FORM works in Australia

You order the panel, we issue the pathology request form, you attend an accredited collection centre, and results come back in Australian SI units with a written explanation.

Fast for 8 to 12 hours with water allowed and collect in the morning, since the panel includes glucose and lipids. Avoid alcohol for 48 to 72 hours beforehand — it transiently raises GGT and triglycerides and can produce an abnormal-looking liver picture that resolves on repeat.

If you already have a treating GP engaged in your care, asking them to request these markers is usually the cheaper route, because pathology requested by a treating practitioner and meeting MBS criteria is generally bulk-billed. Privately requested testing is paid in full and buys speed and marker choice rather than a discount.

• No referral from your own GP is required. Privately requested pathology is arranged under a request from a registered medical practitioner working with our accredited lab partner.
• Collection is a walk-in blood draw at Laverty (Healius) pathology centres Australia-wide (NATA / ISO 15189 accredited).
• Results are returned in Australian SI units — mmol/mol and % for HbA1c, mmol/L for glucose and lipids, U/L for liver enzymes — with a written plain-English explanation.
• Your results are yours. Take them to your GP, an endocrinologist or whichever registered practitioner is managing your care; decisions about any medicine are theirs and yours, not ours.
• Australian ordering is currently pre-sale. Join the waitlist and we will email you when ordering opens.

Better questions to take to your GP

Since the decisions here are clinical, the most useful thing a page like this can offer is a list of questions worth asking the practitioner who can actually answer them.

Walking into a consultation with a recent, complete set of bloods changes it. Instead of the first appointment being 'let's get some tests and see you in a fortnight', the numbers are already on the table and the conversation can be about what they mean.

• What is my current HbA1c, and which band does it sit in?
• Have my liver enzymes and lipids ever been measured, and what were they?
• Has my thyroid function been checked, given the weight change?
• Is there anything in my bloods that should be addressed before considering any treatment?
• If treatment goes ahead, what will you monitor, and how often?
• Is there a PBS-subsidised option for my clinical situation, and what would I pay?